Showing 371-380 of 1791 results for "".
- Multiple Sclerosis Prevalence May Be Twice As High as Previously Thoughthttps://practicalneurology.com/news/multiple-sclerosis-prevalence-may-be-twice-as-high-as-previously-thought/2468830/A study published in the journal Neurology suggests prevalence of multiple sclerosis (MS) in the US is 913,925—more than twice the previous estimate of 400,000 people in
- FDA Recalls Software Used with Surgical Navigation Systemhttps://practicalneurology.com/news/fda-grants-breakthrough-device-designation-for-alzheimers-disease-screening-test/2468857/Medtronic has recalled software used during biopsy procedures due to reports that the products—Synergy Cranial Software and StealthStation S7 Cranial Software—provided incorrect information that could result in serious or life-threatening harm to patients. The FDA has id
- Stem-Cell Transplants Delayed Disease Progression of Multiple Sclerosishttps://practicalneurology.com/news/stem-cell-transplants-delayed-disease-progression-of-multiple-sclerosis/2468861/January 25, 2019—As published in JAMA, interim results of the phase 2 MIST trial (NCT00273364) show that stem-cell treatment resulted in a signific
- New Study Will Evaluate Smart Watch Technology for Help in Preventing Strokeshttps://practicalneurology.com/news/new-study-will-evaluate-smart-watch-technology-for-help-in-preventing-strokes/2468864/January 21, 2019—A new study will analyze the impact of a smart watch (Apple, Cupertino, CA) on early detection and diagnosis of atrial fibrillation (AFib) and the potential to prevent stroke. The large-scale research will start later this year in the US and will be a pragmatic, randomized,
- FDA Approves Generic Vigabatrin for Complex Partial Seizureshttps://practicalneurology.com/news/fda-approves-generic-vigabatrin-for-complex-partial-seizures/2468865/January 21, 2019—The Food and Drug Administration (FDA) has approved generic vigabatrin 500 mg tablets for adjunctive treatment of patients with complex partial seizures, age 10 years and older, who have not responded adequately to other treatments. “We know there has been
- Peter Sayegh, MDhttps://practicalneurology.com/profiles/peter-sayegh-md/L2e8XX/
- Peter A. Calabresi, MDhttps://practicalneurology.com/profiles/peter-a-calabresi-md/jVmGKV/
- Peter V. Sguigna, MDhttps://practicalneurology.com/profiles/peter-v-sguigna-md/OwdAQ6/
- Peter B. Kang, MDhttps://practicalneurology.com/profiles/peter-b-kang-md/7ZrQw7/Univ of New England COM *
- Peter J. Bruno, MDhttps://practicalneurology.com/profiles/peter-j-bruno-md/7Nn96m/